Ryan J. Watts - 01 Jul 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
01 Jul 2021
Transactions value $
-$1,416,300
Form type
4
Filing time
06 Jul 2021, 16:14:11 UTC
Previous filing
03 Jun 2021
Next filing
04 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$231,428 -3,030 -0.14% $76.38 2,207,712 01 Jul 2021 See footnote F1, F2, F3
transaction DNLI Common Stock Sale -$993,470 -12,844 -0.58% $77.35 2,194,868 01 Jul 2021 See footnote F1, F3, F4
transaction DNLI Common Stock Sale -$191,401 -2,459 -0.11% $77.84 2,192,409 01 Jul 2021 See footnote F1, F3, F5
holding DNLI Common Stock 156,691 01 Jul 2021 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.67 to $76.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.67 to $77.665 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.67 to $78.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 Includes 156,691 restricted stock units.